Monimus Capital Management, LP Cytom X Therapeutics, Inc. Transaction History
Monimus Capital Management, LP
- $106 Billion
- Q4 2024
A detailed history of Monimus Capital Management, LP transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Monimus Capital Management, LP holds 364,306 shares of CTMX stock, worth $280,515. This represents 0.35% of its overall portfolio holdings.
Number of Shares
364,306Holding current value
$280,515% of portfolio
0.35%Shares
1 transactions
Others Institutions Holding CTMX
# of Institutions
78Shares Held
49.9MCall Options Held
112KPut Options Held
8.3K-
Tang Capital Management LLC San Diego, CA7.81MShares$6.02 Million0.79% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$4.03 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.16MShares$3.97 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X04.81MShares$3.7 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA3.14MShares$2.42 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $50.8M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...